Opinion
MDL 2445 13-MD-2445
08-22-2022
IN RE SUBOXONE (BUPRENORPHINE HYDROCHLORIDE AND NALOXONE) ANTITRUST LITIGATION THIS DOCUMENT RELATES TO Wisconsin, et al. v. Indivior Inc. et al. Case No. 16-cv-5073 STATE OF WISCONSIN By Attorney General Brad D. Schimel, et al. Plaintiffs, v. INDIVIOR INC. f/k/a RECKITT BENCKISER PHARMACEUTICALS, INC., et al. Defendants. Civil Action No. 16-5073
ORDER
MITCHELL S. GOLDBERG, J.
AND NOW, this 22nd day of August, 2022, upon consideration of Defendant Indivior Inc.'s Motion for Summary Judgment on All Claims (MDL No. 13-2445, Doc. Nos. 699 and 706; Civ. A. No. 16-5073, Doc. No. 450), Defendant Indivior Inc.'s Motion for Summary Judgment Pertaining to Specific Plaintiffs and Remedies (MDL No. 13-2445, Doc. Nos. 699 and 706), the Direct Purchaser and End Payor Plaintiffs' Response (MDL No. 13-2445, Doc. Nos. 731, 732, and 734), the Plaintiff States' Response (Civ. A. No. 16-5073, Doc. Nos. 464, 465), and Indivior's Reply (MDL No. 13-2445, Doc. No. 740; Civ. A. No. 16-5073, Doc. No. 469), and following oral argument, it is hereby ORDERED that both Motions are DENIED.